Expertise in
26
conditions

Dr. Maro N. Ohanian

Internal Medicine
University Of Texas MD Anderson Cancer Center
1515 Holcombe Blvd Unit 428, 
Houston, TX 
Clinical Trials:Currently Recruiting for 1 Trial
Offers Telehealth
Expertise in
26
conditions
University Of Texas MD Anderson Cancer Center
1515 Holcombe Blvd Unit 428, 
Houston, TX 

Overview

Maro Ohanian is a primary care provider, practicing in Internal Medicine in Houston, Texas.

Dr. Ohanian is highly rated in 26 conditions, according to our data. Her clinical expertise encompasses Acute Myeloid Leukemia (AML), Leukemia, Chronic Myelogenous Leukemia (CML), Myelodysplastic Syndrome (MDS), and Bone Marrow Aspiration.

She is actively involved in clinical research, co-authoring 95 peer reviewed articles and participating in 5 clinical trials.

Specialties

Internal Medicine

Licenses

Internal Medicine in TX

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cambia Health Solutions
  • EPO
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Louisiana Healthcare Connections
  • HMO
  • MANAGED MEDICAID PLAN
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Northern Plains Alliance
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE PDP
Northwell Health
  • INSURANCE PLAN
Superior Health Plan
  • MANAGED MEDICAID PLAN
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 9 Less Insurance Carriers -

Locations

University of Texas MD Anderson Cancer Center
1515 Holcombe Blvd Unit 428, Houston, TX 77030

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

Lead-In and Phase II Study of Clofarabine, Etoposide, Cyclophosphamide [CEC], Liposomal Vincristine (VCR), Dexamethasone and Bortezomib in Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) and Lymphoblastic Lymphoma (LL)
Lead-In and Phase II Study of Clofarabine, Etoposide, Cyclophosphamide [CEC], Liposomal Vincristine (VCR), Dexamethasone and Bortezomib in Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) and Lymphoblastic Lymphoma (LL)
Enrollment Status: Recruiting
Publish Date: August 10, 2026
Intervention Type: Biological, Drug
Study Drugs: Bortezomib, Clofarabine, Cyclophosphamide, Dexamethasone, Etoposide, Ofatumumab, Pegfilgrastim, Rituximab, Vincristine Sulfate Liposome
Study Phase: Phase 2
A Phase 1a/b Trial of CG-806 in Patients With Relapsed/Refractory Acute Myeloid Leukemia or Higher-Risk Myelodysplastic Syndromes
A Phase 1a/b Trial of CG-806 in Patients With Relapsed/Refractory Acute Myeloid Leukemia or Higher-Risk Myelodysplastic Syndromes
Enrollment Status: Terminated
Publish Date: March 07, 2025
Intervention Type: Drug
Study Drug: CG-806
Study Phase: Phase 1
A Phase IIa Study of BL-8040 in Combination With Nelarabine for Relapsed or Refractory T-Acute Lymphoblastic Leukemia/ Lymphoblastic Lymphoma
A Phase IIa Study of BL-8040 in Combination With Nelarabine for Relapsed or Refractory T-Acute Lymphoblastic Leukemia/ Lymphoblastic Lymphoma
Enrollment Status: Terminated
Publish Date: October 31, 2023
Intervention Type: Drug
Study Drugs: BL-8040 CD34-Positive Hematopoietic Cells, Nelarabine
Study Phase: Phase 2
A Prospective, Multicenter, Randomized, Open-Label Phase 2, Parallel, Dose Ranging Multidose Study of Thrombosomes® vs Liquid Stored Platelets (LSP) in Bleeding Thrombocytopenic Patients
A Prospective, Multicenter, Randomized, Open-Label Phase 2, Parallel, Dose Ranging Multidose Study of Thrombosomes® vs Liquid Stored Platelets (LSP) in Bleeding Thrombocytopenic Patients
Enrollment Status: Terminated
Publish Date: May 25, 2023
Intervention Type: Biological
Study Drugs: Thrombosomes, Liquid-Stored Platelets
Study Phase: Phase 2
A Phase Ia/b Dose Escalation and Expansion, Multicenter, Open-label, Safety, Pharmacokinetic and Pharmacodynamic Study of APTO-253 in Patients With Relapsed or Refractory Acute Myelogenous Leukemia or High-Risk Myelodysplasia
A Phase Ia/b Dose Escalation and Expansion, Multicenter, Open-label, Safety, Pharmacokinetic and Pharmacodynamic Study of APTO-253 in Patients With Relapsed or Refractory Acute Myelogenous Leukemia or High-Risk Myelodysplasia
Enrollment Status: Terminated
Publish Date: August 22, 2022
Intervention Type: Drug
Study Drug: APTO-253
Study Phase: Phase 1
View 4 Less Clinical Trials

95 Total Publications

Final results of a phase II study of the combination of azacitidine and ruxolitinib in patients with myelofibrosis.
Final results of a phase II study of the combination of azacitidine and ruxolitinib in patients with myelofibrosis.
Journal: Haematologica
Published: May 04, 2026
Similar Doctors
Expertise in
17
conditions
Dr. Preetesh M. Jain
Internal Medicine
Expertise in
17
conditions
Dr. Preetesh M. Jain
Internal Medicine

UT MD Anderson Cancer Center

1515 Holcombe Blvd, 
Houston, TX 
 (0.3 miles away)
713-792-1101
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Preetesh Jain is a primary care provider, practicing in Internal Medicine in Houston, Texas. Dr. Jain is highly rated in 17 conditions, according to our data. His clinical expertise encompasses Mantle Cell Lymphoma (MCL), Non-Hodgkin Lymphoma, Leukemia, Chronic Lymphocytic Leukemia (CLL), and Bone Marrow Aspiration.

Expertise in
14
conditions
Dr. Shreyaskumar R. Patel
Internal Medicine
Expertise in
14
conditions
Dr. Shreyaskumar R. Patel
Internal Medicine

Office

1515 Holcombe Blvd # 450, 
Houston, TX 
 (0.3 miles away)
713-794-4632
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Shreyaskumar Patel is a primary care provider, practicing in Internal Medicine in Houston, Texas. Dr. Patel is highly rated in 14 conditions, according to our data. His clinical expertise encompasses Synovial Sarcoma, Osteosarcoma, Gastrointestinal Stromal Tumor, Rhabdomyosarcoma, and Osteotomy.

Expertise in
17
conditions
Dr. Dai Chihara
Internal Medicine
Expertise in
17
conditions
Dr. Dai Chihara
Internal Medicine

MD Anderson

1515 Holcombe Blvd, 
Houston, TX 
 (0.3 miles away)
713-792-2121
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Dai Chihara is a primary care provider, practicing in Internal Medicine in Houston, Texas. Dr. Chihara is highly rated in 17 conditions, according to our data. His clinical expertise encompasses Non-Hodgkin Lymphoma, Follicular Lymphoma, Peripheral T-Cell Lymphoma, T-Cell Lymphoma, and Bone Marrow Aspiration.

Frequently Asked Questions about Dr. Maro N. Ohanian

How do I make an appointment with Dr. Maro N. Ohanian?

You can book an appointment with Dr. Maro N. Ohanian by calling their office at 713-792-8760. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Maro N. Ohanian a top-rated expert for Acute Myeloid Leukemia (AML)?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Maro N. Ohanian is classified as an Elite expert for Acute Myeloid Leukemia (AML), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Maro N. Ohanian specialize in?

While Dr. Maro N. Ohanian is a Internal Medicine, they have specific expertise in Acute Myeloid Leukemia (AML), Leukemia, and Chronic Myelogenous Leukemia (CML). MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Internal Medicine.

Does Dr. Maro N. Ohanian participate in research or clinical trials?

Yes. Dr. Maro N. Ohanian has published 95 articles and abstracts on conditions like Acute Myeloid Leukemia (AML). You can view a list of Dr. Maro N. Ohanian's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Maro N. Ohanian accept my insurance?

Dr. Maro N. Ohanian accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 713-792-8760 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Ohanian's expertise for a condition
ConditionClose
View All 15 Distinguished Conditions
View All 9 Advanced Conditions
View All 25 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile